Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875121 | 0.78 | KDM4E (0.59) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 | |
| SCHEMBL67456 | 0.78 | — | — | |
| SCHEMBL2155406 | 0.75 | CYP19A1 (0.40) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 | |
| SCHEMBL14157151 | 0.75 | MAPT (0.53) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 | |
| SCHEMBL1533682 | 0.73 | — | — | |
| SCHEMBL21823786 | 0.72 | CYP19A1 (0.50) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 | |
| SCHEMBL18715424 | 0.72 | — | — | |
| SCHEMBL21823929 | 0.72 | ACHE (0.39) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 | |
| SCHEMBL21823772 | 0.72 | CYP19A1 (0.33) | CYP19A1KDM4ERAB9A | |
| SCHEMBL15689010 | 0.71 | PDE10A (0.34) | CYP19A1KDM4ELMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773074-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| EP-3896062-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-20210047285-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-02-18 | — | — | US | disclosed |
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-12-08 | — | — | US | disclosed |
| CN-111285850-A | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-06-16 | — | — | CN | disclosed |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-11 | — | — | US | disclosed |
| EP-2417177-A1 | OLIGOMERIC AND POLYMERIC SEMICONDUCTORS BASED ON THIENOTHIAZOLES | Heraeus Precious Metals GmbH & Co. KG (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115623-A1 | OLIGOMERIC AND POLYMERIC SEMICONDUCTORS BASED ON THIENOTHIAZOLES | H.C.STARCK CLEVIOS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115623-A1 | OLIGOMERIC AND POLYMERIC SEMICONDUCTORS BASED ON THIENOTHIAZOLES | H.C.STARCK CLEVIOS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | PPOX, TST, COX6C | CYP19A1 1079/4885KDM4E 3896/4885LMNA 4885/4885 |
| US-11773074-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | PPOX, TST, COX6C | CYP19A1 1079/4885KDM4E 3896/4885LMNA 4885/4885 |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | PPOX, TST, COX6C | CYP19A1 1079/4885KDM4E 3896/4885LMNA 4885/4885 |
| US-20210047285-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | PPOX, TST, COX6C | CYP19A1 1079/4885KDM4E 3896/4885LMNA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.